Amgen heads to Phase II with lead BiTE tarlatamab

One of the few remaining bispecific antibodies from Amgen’s BiTE platform is heading into a potentially registrational Phase II study after a positive efficacy readout in the challenging small cell lung cancer indication.

At the World Conference on Lung Cancer on Monday, Amgen Inc. (NASDAQ:AMGN) reported that tarlatamab, a bispecific T cell engager targeting DLL3 and CD3, led to an overall response rate (ORR) of 29%, including unconfirmed responses, in 105 small cell lung cancer (SCLC) patients who had been treated with a median of two prior therapies. The responses included two confirmed complete and 22 confirmed partial responses...